Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.

Topline data were announced from a phase 3 trial evaluating Keytruda plus Lenvima with chemotherapy in advanced gastroesophageal cancer.

Merck’s Keytruda has been used against dozens of different cancers in millions of patients, making it the top-selling drug in the world, with over $25 billion in revenue in 2023. Opdivo ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...

Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab), which was approved by the FDA for the same HCC indication in September 2017.

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...